Last reviewed · How we verify
Venofer®
Venofer® is an iron sucrose complex that replenishes iron stores in patients with iron deficiency anemia, particularly those with chronic kidney disease on hemodialysis.
Venofer® is an iron sucrose complex that replenishes iron stores in patients with iron deficiency anemia, particularly those with chronic kidney disease on hemodialysis. Used for Iron deficiency anemia in patients with chronic kidney disease on hemodialysis, Iron deficiency anemia in patients with chronic kidney disease not on dialysis, Iron deficiency anemia in patients on peritoneal dialysis.
At a glance
| Generic name | Venofer® |
|---|---|
| Also known as | Endovenous treatment with Venofer 300mg every 3 month, iron sucrose tablets |
| Sponsor | Azad Pharma AG |
| Drug class | Iron replacement agent |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Iron sucrose is a stable complex of iron (III) hydroxide with sucrose that allows safe intravenous administration of iron. The iron is released and incorporated into hemoglobin and myoglobin, restoring oxygen-carrying capacity and correcting anemia. It is particularly useful in dialysis patients who cannot absorb oral iron adequately and lose blood during dialysis.
Approved indications
- Iron deficiency anemia in patients with chronic kidney disease on hemodialysis
- Iron deficiency anemia in patients with chronic kidney disease not on dialysis
- Iron deficiency anemia in patients on peritoneal dialysis
Common side effects
- Hypotension
- Headache
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Injection site reactions
Key clinical trials
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Pilot Study Evaluating the Advantages of Sucrosomial® Iron Post-operative Supplementation vs Standard of Care After Cardiac Surgery (EARLY_PHASE1)
- Bioequivalence Study of Iron Sucrose Injection in Healthy Participants (PHASE1)
- Safety and Tolerability of 200mg and 100mg of Venofer Administered to Hemodialysis(HD) Patients (PHASE4)
- Bioequivalence Study of Iron Sucrose Injection in Healthy Subjects (PHASE1)
- Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-Dialysis Chronic Kidney Disease Patients (PHASE4)
- Iron Isomaltoside Compared With Iron Sucrosein Peritoneal Dialysis Patients (NA)
- To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Venofer® CI brief — competitive landscape report
- Venofer® updates RSS · CI watch RSS
- Azad Pharma AG portfolio CI